Evaluation of COVID-19 Disease and the Effect of Trends in Intervention Measures: The Pediatric Perspective from a Tertiary Care Hospital in Turkey.
Journal
Balkan medical journal
ISSN: 2146-3131
Titre abrégé: Balkan Med J
Pays: Turkey
ID NLM: 101571817
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
entrez:
18
7
2021
pubmed:
19
7
2021
medline:
24
7
2021
Statut:
ppublish
Résumé
COVID-19 is an emerging disease of global public health concern. To evaluate the epidemiological, clinical, laboratory, and radiologic findings and the clinical outcomes of children who were diagnosed with SARS-CoV-2 by polymerase chain reaction (PCR), and to evaluate the effect of the trends in intervention measures. Between April 2, 2020 and January 16, 2021, children aged 0-18 years who had presented at the pediatric emergency department and were diagnosed with confirmed SARS-CoV-2 by PCR were enrolled. Details on demographics, epidemiologic characteristics, clinical findings, laboratory data, and radiologic investigations, hospital admissions, and prognosis were recorded. According to clinical severity, patients were divided into 5 groups as asymptomatic, mild, moderate, severe, or critical. We classified the outbreak into 3 periods. The first was between April 2, 2020, the date when the first pediatric case of our hospital was detected, and June 1, 2020, when restrictive measures were relaxed. The second period was between June 1, 2020 and November 15, 2020, when restrictive measures were reimplemented. The third period was between November 15, 2020 and January 16, 2021. A total of 600 patients [median age: 10.3 years (IQR: 4.4-15.1); 304 females] were enrolled. Among them, 25.0% were asymptomatic, while the 3 most common symptoms among symptomatic cases were fever, cough, and fatigue. There was contact with a COVID-19 PCRpositive individual in 73.5% of the cases, with 76.6% of those being a household contact. There were 23 (3.9%) moderate, severe, or critical cases in terms of clinical severity. The presence of chronic disease, a pathological physical chest examination, and procalcitonin levels of >0.05 ng/mL were identified as predictors of being moderate, severe, or critical. Twenty-four (4.0%) patients were admitted to the hospital; 14 (2.3%) to the ward and 10 (1.6%) to the pediatric intensive care unit. In the second intervention period, we observed a rapidly increasing number of new cases daily, especially in August. From September, an increase was observed, being particularly marked from October to November 18. Since then, there was a decrease in the daily number of cases. The majority of the cases were asymptomatic or had a mild clinical presentation. The presence of chronic disease, a pathological physical chest examination, and procalcitonin levels of >0.05 ng/mL were identified as predictors of being moderate, severe, or critical in terms of clinical severity. Strict intervention measures seem to be effective in containing the spread of COVID-19.
Sections du résumé
BACKGROUND
COVID-19 is an emerging disease of global public health concern.
AIMS
To evaluate the epidemiological, clinical, laboratory, and radiologic findings and the clinical outcomes of children who were diagnosed with SARS-CoV-2 by polymerase chain reaction (PCR), and to evaluate the effect of the trends in intervention measures.
STUDY DESIGN
Between April 2, 2020 and January 16, 2021, children aged 0-18 years who had presented at the pediatric emergency department and were diagnosed with confirmed SARS-CoV-2 by PCR were enrolled.
METHODS
Details on demographics, epidemiologic characteristics, clinical findings, laboratory data, and radiologic investigations, hospital admissions, and prognosis were recorded. According to clinical severity, patients were divided into 5 groups as asymptomatic, mild, moderate, severe, or critical. We classified the outbreak into 3 periods. The first was between April 2, 2020, the date when the first pediatric case of our hospital was detected, and June 1, 2020, when restrictive measures were relaxed. The second period was between June 1, 2020 and November 15, 2020, when restrictive measures were reimplemented. The third period was between November 15, 2020 and January 16, 2021.
RESULTS
A total of 600 patients [median age: 10.3 years (IQR: 4.4-15.1); 304 females] were enrolled. Among them, 25.0% were asymptomatic, while the 3 most common symptoms among symptomatic cases were fever, cough, and fatigue. There was contact with a COVID-19 PCRpositive individual in 73.5% of the cases, with 76.6% of those being a household contact. There were 23 (3.9%) moderate, severe, or critical cases in terms of clinical severity. The presence of chronic disease, a pathological physical chest examination, and procalcitonin levels of >0.05 ng/mL were identified as predictors of being moderate, severe, or critical. Twenty-four (4.0%) patients were admitted to the hospital; 14 (2.3%) to the ward and 10 (1.6%) to the pediatric intensive care unit. In the second intervention period, we observed a rapidly increasing number of new cases daily, especially in August. From September, an increase was observed, being particularly marked from October to November 18. Since then, there was a decrease in the daily number of cases.
CONCLUSION
The majority of the cases were asymptomatic or had a mild clinical presentation. The presence of chronic disease, a pathological physical chest examination, and procalcitonin levels of >0.05 ng/mL were identified as predictors of being moderate, severe, or critical in terms of clinical severity. Strict intervention measures seem to be effective in containing the spread of COVID-19.
Identifiants
pubmed: 34274911
doi: 10.5152/balkanmedj.2021.21045
pmc: PMC8880974
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
222-228Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
PLoS One. 2020 Oct 1;15(10):e0239802
pubmed: 33002041
EClinicalMedicine. 2020 Jun 26;24:100433
pubmed: 32766542
Pediatr Infect Dis J. 2020 Dec;39(12):e388-e392
pubmed: 33031141
JAMA Pediatr. 2020 Sep 1;174(9):868-873
pubmed: 32392288
Arch Acad Emerg Med. 2020 Apr 18;8(1):e50
pubmed: 32440661
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
Hosp Pediatr. 2021 Jan;11(1):71-78
pubmed: 33033078
JAMA. 2020 Feb 25;323(8):707-708
pubmed: 31971553
Lancet Infect Dis. 2020 Jun;20(6):689-696
pubmed: 32220650
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Front Pediatr. 2020 Sep 04;8:542
pubmed: 33014936
J Infect. 2020 Aug;81(2):e11-e15
pubmed: 32360500
Pediatr Int. 2021 Sep;63(9):1055-1061
pubmed: 33426754
Clin Infect Dis. 2020 Sep 12;71(6):1547-1551
pubmed: 32112072
Clin Infect Dis. 2020 Dec 3;71(9):2469-2479
pubmed: 32392337
Pediatrics. 2021 Jan;147(1):
pubmed: 33055228
Pediatric Health Med Ther. 2020 Sep 21;11:385-392
pubmed: 33061744
Monatsschr Kinderheilkd. 2020;168(7):615-627
pubmed: 32317808
Pediatr Pulmonol. 2020 Dec;55(12):3587-3594
pubmed: 32991038
Emerg Infect Dis. 2020 Oct;26(10):2465-2468
pubmed: 32673193
Cureus. 2020 Sep 12;12(9):e10413
pubmed: 33062530
Hong Kong Med J. 2021 Feb;27(1):35-45
pubmed: 32994372
Pediatrics. 2020 Aug;146(2):
pubmed: 32457213
Turk J Med Sci. 2020 Apr 18;50(SI-1):489-494
pubmed: 32304192
PLoS One. 2020 Oct 15;15(10):e0239389
pubmed: 33057434
J Pediatr. 2020 Dec;227:45-52.e5
pubmed: 32827525
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508